306 related articles for article (PubMed ID: 19340428)
21. Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment.
Morabito F; Cutrona G; Mosca L; D'Anca M; Matis S; Gentile M; Vigna E; Colombo M; Recchia AG; Bossio S; De Stefano L; Maura F; Manzoni M; Ilariucci F; Consoli U; Vincelli I; Musolino C; Cortelezzi A; Molica S; Ferrarini M; Neri A
Leuk Res; 2015 Aug; 39(8):840-5. PubMed ID: 26038121
[TBL] [Abstract][Full Text] [Related]
22. EXPRESSION OF LIPOPROTEIN LIPASE AND c-MYC ONCOGENE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AFFECTED BY THE CHORNOBYL ACCIDENT.
Bilous NI; Abramenko IV; Chumak AA; Diagil IS; Martina ZV
Probl Radiac Med Radiobiol; 2020 Dec; 25():421-429. PubMed ID: 33361851
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
Grever MR; Lucas DM; Dewald GW; Neuberg DS; Reed JC; Kitada S; Flinn IW; Tallman MS; Appelbaum FR; Larson RA; Paietta E; Jelinek DF; Gribben JG; Byrd JC
J Clin Oncol; 2007 Mar; 25(7):799-804. PubMed ID: 17283363
[TBL] [Abstract][Full Text] [Related]
24. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
Thompson PA; Tam CS; O'Brien SM; Wierda WG; Stingo F; Plunkett W; Smith SC; Kantarjian HM; Freireich EJ; Keating MJ
Blood; 2016 Jan; 127(3):303-9. PubMed ID: 26492934
[TBL] [Abstract][Full Text] [Related]
25. [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
Smolej L; Andrýs C; Krejsek J; Belada DZ; Zák P; Siroký O; Malý J
Vnitr Lek; 2007 Nov; 53(11):1171-6. PubMed ID: 18277626
[TBL] [Abstract][Full Text] [Related]
26. Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia.
Nückel H; Hüttmann A; Klein-Hitpass L; Schroers R; Führer A; Sellmann L; Dührsen U; Dürig J
Leuk Lymphoma; 2006 Jun; 47(6):1053-61. PubMed ID: 16840197
[TBL] [Abstract][Full Text] [Related]
27. High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia.
Heintel D; Kienle D; Shehata M; Kröber A; Kroemer E; Schwarzinger I; Mitteregger D; Le T; Gleiss A; Mannhalter C; Chott A; Schwarzmeier J; Fonatsch C; Gaiger A; Döhner H; Stilgenbauer S; Jäger U;
Leukemia; 2005 Jul; 19(7):1216-23. PubMed ID: 15858619
[TBL] [Abstract][Full Text] [Related]
28. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia.
Oppezzo P; Vasconcelos Y; Settegrana C; Jeannel D; Vuillier F; Legarff-Tavernier M; Kimura EY; Bechet S; Dumas G; Brissard M; Merle-Béral H; Yamamoto M; Dighiero G; Davi F;
Blood; 2005 Jul; 106(2):650-7. PubMed ID: 15802535
[TBL] [Abstract][Full Text] [Related]
29. Clinical features and outcome of Chinese patients with monoclonal B-cell lymphocytosis.
Xu W; Li JY; Wu YJ; Cao X; Fan L; Qiao C; Liu Q; Yao L; Miao KR
Leuk Res; 2009 Dec; 33(12):1619-22. PubMed ID: 19250675
[TBL] [Abstract][Full Text] [Related]
30. Oral fludarabine treatment of cutaneous infiltration in a patient with B-cell chronic lymphocytic leukaemia.
Ural AU; Kubar A; Avcu F; Tastan HB; Safali M; Nevruz O; Cetin T
Clin Exp Dermatol; 2007 Mar; 32(2):151-4. PubMed ID: 17244344
[TBL] [Abstract][Full Text] [Related]
31. Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status.
Lech-Maranda E; Grzybowska-Izydorczyk O; Wyka K; Mlynarski W; Borowiec M; Antosik K; Cebula-Obrzut B; Makuch-Lasica H; Nowak G; Klimkiewicz-Wojciechowska G; Wawrzyniak E; Bilinski P; Robak T; Warzocha K
Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):477-86. PubMed ID: 22945689
[TBL] [Abstract][Full Text] [Related]
32. Pattern and distribution of immunoglobulin VH gene usage in a cohort of B-CLL patients from a Northeastern region of Italy.
Donisi PM; Di Lorenzo N; Riccardi M; Paparella A; Sarpellon C; Zupo S; Bertoldero G; Minotto C; Stracca-Pansa V
Diagn Mol Pathol; 2006 Dec; 15(4):206-15. PubMed ID: 17122648
[TBL] [Abstract][Full Text] [Related]
33. High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival.
Kotaskova J; Tichy B; Trbusek M; Francova HS; Kabathova J; Malcikova J; Doubek M; Brychtova Y; Mayer J; Pospisilova S
J Mol Diagn; 2010 May; 12(3):328-34. PubMed ID: 20228263
[TBL] [Abstract][Full Text] [Related]
34. Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia.
Visco C; Moretta F; Falisi E; Facco M; Maura F; Novella E; Nichele I; Finotto S; Giaretta I; Ave E; Perbellini O; Guercini N; Scupoli MT; Trentin L; Trimarco V; Neri A; Semenzato G; Rodeghiero F; Pizzolo G; Ambrosetti A
Am J Hematol; 2013 Apr; 88(4):277-82. PubMed ID: 23450508
[TBL] [Abstract][Full Text] [Related]
35. Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
Visentin A; Facco M; Gurrieri C; Pagnin E; Martini V; Imbergamo S; Frezzato F; Trimarco V; Severin F; Raggi F; Scomazzon E; Pravato S; Piazza F; Semenzato G; Trentin L
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):678-685.e4. PubMed ID: 31371221
[TBL] [Abstract][Full Text] [Related]
36. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
Böttcher S; Ritgen M; Fischer K; Stilgenbauer S; Busch RM; Fingerle-Rowson G; Fink AM; Bühler A; Zenz T; Wenger MK; Mendila M; Wendtner CM; Eichhorst BF; Döhner H; Hallek MJ; Kneba M
J Clin Oncol; 2012 Mar; 30(9):980-8. PubMed ID: 22331940
[TBL] [Abstract][Full Text] [Related]
37. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia.
Pfitzner T; Reiser M; Barth S; Borchmann P; Schulz H; Schinköthe T; Oberhäuser F; Wessels J; Tur M; Diehl V; Engert A
Ann Hematol; 2002 May; 81(5):258-66. PubMed ID: 12029535
[TBL] [Abstract][Full Text] [Related]
38. Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups.
MacIntyre DA; Jiménez B; Lewintre EJ; Martín CR; Schäfer H; Ballesteros CG; Mayans JR; Spraul M; García-Conde J; Pineda-Lucena A
Leukemia; 2010 Apr; 24(4):788-97. PubMed ID: 20090781
[TBL] [Abstract][Full Text] [Related]
39. Analysis of LPL gene expression in patients with chronic lymphocytic leukemia.
Bilous N; Abramenko I; Chumak A; Dyagil I; Martina Z
Exp Oncol; 2019 Mar; 41(1):39-45. PubMed ID: 30932419
[TBL] [Abstract][Full Text] [Related]
40. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors.
Rossi D; Sozzi E; Puma A; De Paoli L; Rasi S; Spina V; Gozzetti A; Tassi M; Cencini E; Raspadori D; Pinto V; Bertoni F; Gattei V; Lauria F; Gaidano G; Forconi F
Br J Haematol; 2009 Jun; 146(1):64-75. PubMed ID: 19438485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
